A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination With Systemic Therapies in Patients With Advanced Solid Tumors and Lymphomas
Overview
- Phase
- Phase 1
- Intervention
- CS5001
- Conditions
- Advanced Solid Tumor
- Sponsor
- CStone Pharmaceuticals
- Enrollment
- 480
- Locations
- 37
- Primary Endpoint
- Maximum Tolerated Dose (MTD) of CS5001 if any (for dose escalation part)
- Status
- Recruiting
- Last Updated
- 8 months ago
Overview
Brief Summary
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.
Investigators
Eligibility Criteria
Inclusion Criteria
- •For solid tumor patients of dose escalation, they must have pathologically confirmed, unresectable advanced solid tumor with disease progression on or after at least 1 line of prior systemic therapy.
- •For Lymphoma patients of dose escalation, they must have pathologically confirmed Hodgkin and non-Hodgkin B-cell lymphoma as defined per 2016 World Health Organization(WHO) classification, with disease progression on or after at least 2 lines of prior systemic therapy.
- •For mono-therapy cohorts, eligible patients must have pathologically confirmed relapsed/refractory (R/R) lymphomas or advanced solid tumors, and have demonstrated failure with previous line(s) of standard-of-care treatment. Patients in the solid tumor cohort must exhibit ROR1-positive expression in their baseline tumor tissues. For combination therapy cohorts, DLBCL patients must either be treatment-naïve or have experienced failure with at least one prior line of standard-of-care therapy to qualify for treatment with CS5001 in combination with first-line or subsequent standard-of-care therapies for DLBCL. Solid tumor patients must have pathologically confirmed disease, be naïve to PD-1/PD-L1 inhibitors, and have at least failed first-line therapy or standard-of-care treatment.
- •For dose escalation, with at least one evaluable lesion as defined per Response Evaluation Criteria in Solid Tumours(RECIST) v1.1 solid tumor or per 2014 Lugano Classification Criteria for lymphoma, respectively. For dose expansion, with at least one measurable lesion as defined per RECIST v1.1 solid tumor or per 2014 Lugano Classification Criteria for lymphoma, respectively.
- •Life expectancy \> 3 months.
- •Eastern Cooperative Oncology Group(ECOG) performance status 0-
- •Have adequate organ function.
Exclusion Criteria
- •Has disease that is suitable for local treatment administered with curative intent. For lymphoma, candidacy for hematopoietic stem cell transplantation based on the Investigator's judgment.
- •Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
- •For dose expansion: Participation in other studies involving therapies targeting ROR1 prior to study entry and/or during study participation.
- •Has known central nervous system (CNS) lymphoma or solid tumor CNS metastasis that is either symptomatic, untreated, or requires therapy.
- •Has other acute or chronic medical or psychiatric conditions.
- •Has a diagnosis of immunodeficiency, or has an active autoimmune disease or other conditions that require systemic steroid therapy.
- •Has peripheral edema, pericardial effusion, or ascites indicated for medical intervention or limiting activity of daily life. Or with a known history of peripheral vasculopathies.
- •Patients with any active infections requiring systemic therapy within 2 weeks prior to the administration of the first dose of the study drug.
- •Patients known to be human immunodeficiency virus (HIV)-positive or have acquired immune deficiency syndrome (AIDS).
- •Significant cardiovascular disease within 6 months prior to the first dose of the study drug.
Arms & Interventions
Dose escalation
Intervention: CS5001
Dose expansion
Intervention: CS5001
Dose expansion
Intervention: Rituximab
Dose expansion
Intervention: Gemcitabine
Dose expansion
Intervention: Oxaliplatin
Dose expansion
Intervention: Lenalidomide
Dose expansion
Intervention: Cyclophosphamide
Dose expansion
Intervention: Doxorubicin
Dose expansion
Intervention: Vincristine
Dose expansion
Intervention: Prednisone
Outcomes
Primary Outcomes
Maximum Tolerated Dose (MTD) of CS5001 if any (for dose escalation part)
Time Frame: About 6 months
Participants will receive CS5001 for injection once every three weeks. The MTD will be determined by the number of participants who experience a dose limiting toxicity (DLT).
Recommended Phase 2 Dose(RP2D) of CS5001 (for dose escalation part)
Time Frame: About 6 months
The selection of RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The RP2D may be the MTD or may be a lower dose within the tolerable dose range.
Incident and severity of adverse events
Time Frame: Until 90 days since the last dose of investigational product or until initiation of a new anti-cancer treatment, whichever occurs first
Objective Response Rate (ORR) (for dose expansion)
Time Frame: Up to 2 years
The percentage of participants with a CR or PR based on 2014 Lugano Classification Criteria for lymphomas, iwCLL 2018 guidelines for CLL/SLL and RECIST v1.1 for solid tumors.
Secondary Outcomes
- Concentration of CS5001 total antibody(Up to 30 days since the last dose of or until initiation of a new anti-cancer treatment, whichever occurs first)
- Concentration of anti-CS5001 antibodies(Up to 30 days since the last dose of or until initiation of a new anti-cancer treatment, whichever occurs first)